Table 1 Demographic, clinical, pathological, and treatment characteristics of the BRAF+ and BRAF− melanoma groups
Variable | BRAF+ (n = 53) | BRAF− (n = 52) | P |
|---|---|---|---|
Age (years) | |||
≤ 50 | 23 (43%) | 10 (19%) | 0.01 |
> 50 | 30 (57%) | 42 (81%) | |
Sex | |||
Male | 36 (68%) | 34 (65%) | 0.89 |
Female | 17 (32%) | 18 (35%) | |
Site of primary | |||
Head and Neck | 10 (19%) | 23 (43%) | |
Trunk | 18 (34%) | 6 (11%) | 0.02 |
Arm | 10 (19%) | 9 (17%) | |
Leg | 11 (21%) | 9 (17%) | |
Unknown (found only in LNs) | 4 (8%) | 5 (9%) | |
Site of LND | |||
Cervical | 7 (19%) | 14 (44%) | 0.09 |
Axillary | 18 (50%) | 11 (34%) | |
Inguinal | 11 (31%) | 7 (22%) | |
Depth of invasion at biopsy | |||
T1 (≤ 1 mm) | 3 (6%) | 1 (2%) | |
T2 (> 1–2 mm) | 4 (8%) | 2 (4%) | 0.58 |
T3 (> 2–4 mm) | 5 (10%) | 8 (16%) | |
T4 (> 4 mm) | 16 (32%) | 13 (27%) | |
Unknown | 22 (44%) | 25 (51%) | |
Ulceration in biopsy | |||
No | 17 (32%) | 11 (21%) | 0.38 |
Yes | 19 (36%) | 19 (37%) | |
Unknown | 17 (32%) | 22 (42%) | |
# of Mitosis in Biopsy (mm2) | |||
0–2 | 10 (19%) | 4 (8%) | 0.04 |
3–5 | 6 (11%) | 11 (21%) | |
> 5 | 20 (38%) | 11 (21%) | |
Unknown | 17 (32%) | 26 (50%) | |
# of LNs positive in LND | |||
1 (N1) | 8 (35%) | 8 (42%) | 0.86 |
2 or 3 (N2) | 14 (61%) | 10 (53%) | |
4 + (N3) | 1 (4%) | 1 (5%) | |
ECE found in LND | |||
Yes | 20 (56%) | 14 (44%) | 0.47 |
No | 16 (44%) | 18 (56%) | |